The Global Market for Circulating Tumor Cell (CTC) Diagnostics is Projected to Reach US$14.1 Billion by 2022
Growing Incidence of Cancer Drives the Market
for Circulating Tumor Cell (CTC) Diagnostics, According to a New Report by Global Industry Analysts, Inc.
GIA
launches comprehensive analysis of industry segments, trends, growth drivers,
market size, share and demand forecasts on the global Circulating Tumor Cell
(CTC) Diagnostics market. The global market for Circulating Tumor Cell (CTC)
Diagnostics is projected to reach US$14.1 billion by 2022, driven by the rising incidence of cancer, increasing
need for advanced detection technologies, research breakthroughs enabling better
understanding of disease dynamics and technological advancements.
Cancer
has emerged as one of the most dreaded diseases worldwide, with the distinction
of being the second leading cause of death. Aging population and changing
lifestyles are driving cancer incidence and deaths, which are in turn driving
the need for effective diagnostic tools that help identify cancer early,
prevent metastases and treat them effectively. Considerable research efforts
are underway to develop new and innovative cancer diagnostic, prognostic and
treatment procedures to detect cancers early and treat them effectively.
Circulating Tumor Cell (CTC) is one such technology. CTCs are tumor cells that
originate from primary tumors or metastases and move freely in the peripheral
blood. CTC isolation, detection and their molecular characterization provide
vital insights into the stage of cancer, identify the primary and secondary
organs affected or metastases for which CTCs act as seeds, and may also be
helpful in the timely planning of treatment solutions. Through liquid biopsy, CTCs
hold potential to present a therapeutically equivalent, non-invasive test for
cancer diagnosis and prognosis that can create significant appeal among
patients and doctors alike. Real time sampling and monitoring are the major
advantages of CTCs and liquid biopsy analysis, empowering them to monitor
disease progression and make changes to administered therapy in real-time based
on information from CTC analysis.
Much
of the progress in recent years has been in the area of CTC enrichment through
the development of microfluidic devices, while CTC discovery and validation
remain in nascent stages. The launch of CellSearch system for CTC enumeration
and its promising prognostic value further increased interest in the area of
CTCs for their use in evaluation of tumors. Microdevices, however, have
garnered considerable attention in recent years for CTC enrichment and
enumeration due to their cost-effectiveness, simplicity, speed, and automated
immunoassay. Gravity-fed microfluidic devices represent new CTC enrichment
technology that ousts limitations in conventional technologies. Physical property-based enrichment technologies are losing relevance in the wake of growing emphasis
on diversity in CTC shape and size, resulting in development and use of more
sophisticated, label-free technologies such as those involving
dielectrophoresis and photoacoustic flow cytometry.
As
stated by the new market research report on Circulating Tumor Cell (CTC) Diagnostics, the United States represents the largest market
worldwide, supported by effervescent research activity in cancer diagnostics; and
challenges in healthcare posed by a rapidly aging society. Asia-Pacific ranks
as the fastest growing market with a CAGR of 22.1% over the analysis period,
led by changing lifestyles, surging incidence of cancer, improving healthcare
infrastructure, growing per capita healthcare spending; committed efforts to close
the disparities in cancer care in developing markets; and the resulting rise in
investments in disruptive cancer diagnostics with the potential to improve quality
of cancer care.
Major
players covered in the report include QIAGEN Hannover GmbH, ApoCell, Inc.,
Biocep Ltd., Biocept, Inc., Biofluidica Microtechnologies LLC, Celltraffix
Inc., Clearbridge Biomedics, Creatv Microtech, Inc., Cynvenio Biosystems, Inc.,
Epic Biosciences Inc., Fluxion Biosciences, Inc., Ikonisys, Inc.,
IVDiagnostics, Inc., Janssen Diagnostics LLC, RARECELLS SAS, ScreenCell and
STEMCELL Technologies, Inc. among others.
The
research report titled “Circulating Tumor Cell (CTC) Diagnostics: A Global
Strategic Business Report” announced
by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers,
acquisitions and other strategic industry activities of global companies. The
report provides market estimates and projections for Circulating Tumor Cell
(CTC) Diagnostics in value terms for all major geographic markets such as
United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia
and Rest of Europe), Asia-Pacific and Rest of World.
Global
Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights
Reserved.
Comments
Post a Comment